National Research Q1 EPS falls to $0.28 from $0.34; capital allocation unchanged

NRC HEALTH

2023-Q1 EPS reported $0.28 revenue$36,473,000

Diluted EPS $0.28 for Q1 2023, down from $0.34 in Q1 2022.
Company funded $2.9M for innovation and growth, $3.0M for dividends, $2.0M for share repurchases.
Board maintains capital allocation priorities: innovation, M&A, dividends, buybacks.
Announced MyView to integrate patient insights into EHR to support personalized care.
Expanding sales and marketing resources for Human Understanding Program.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

NRC HEALTH reported the first quarter ended March 31, 2023 results: EPS Diluted earnings per share decreased to $0.28 for the quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
EPS: Diluted earnings per share decreased to $0.28 for the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 2, 2023, National Research Corporation, a Delaware corporation (the "Company"), issued a press release announcing its financial and operating results for the first quarter ended March 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

NRC HEALTH filing history →

Source: SEC EDGAR

accession 0001437749-23-012493

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.